兽用生物制品

Search documents
永顺生物发布2025年半年报:营收净利实现双增长,高质量发展显成效
Cai Jing Wang· 2025-08-27 03:22
8月26日晚间,永顺生物(839729.BJ)发布了2025年半年度报告。在生猪养殖业回暖和行业竞争加剧的双重背景下,公司凭借扎实的经营策略和持续的研发 创新,实现了营业收入与净利润的双增长,展现了强劲的盈利能力。 报告期内,公司综合毛利率同比上升1.85个百分点,同时,公司经营活动现金流表现稳健,上半年经营活动产生的现金流量净额为4335.06万元,同比增长 23.21%,资产负债结构健康,为公司的高质量发展奠定了坚实基础。 业绩稳步增长,猪用疫苗成核心驱动力 2025年上半年,永顺生物交出了一份亮眼的"成绩单"。公司实现营业收入1.22亿元,同比增长2.14%;归母净利润1972.09万元,同比增长26.95%。尤其值得 注意的是,在扣除股份支付影响后,归属于上市公司股东的净利润达到2341.32万元,同比大幅增长50.72%,凸显出公司强劲的盈利能力。 年报显示,营业收入的增长主要得益于猪用疫苗市场的回暖。受下游猪价上涨及中小养殖户复养积极性提升等因素影响,永顺生物的猪用活疫苗销量同比上 升13.95%,带动相关销售收入增加5.94%。此外,其他疫苗收入也实现了63.86%的显著增长,其中猪圆环疫苗收入 ...
申联生物(688098.SH)20CM三连板!
Ge Long Hui A P P· 2025-08-19 02:36
格隆汇8月19日|申联生物(688098.SH)今日再度20CM涨停,为连续第三日涨停,报价15.4元,创2021年 3月以来新高。 申联生物昨晚发布股票交易异常波动公告称,经公司自查,并发函向控股股东、实际控制人核实,截至 本公告披露日,公司不存在应披露而未披露的重大事项。公司目前生产经营正常,生产经营未发生重大 变化。公司目前的主营业务是兽用生物制品,艾滋病单克隆抗体等创新药管线由联营公司扬州世之源生 物科技有限责任公司独立运营,相关业务具有研发周期长,投入大,研发风险高的特点。 ...
晚间公告丨8月18日这些公告有看头
第一财经· 2025-08-18 15:49
2025.08. 18 仲景食品:子公司拟出售土地、厂房等资产 仲景食品公告,鉴于野生蓝莓供应环境的变化,为优化公司资产配置并提升运营效率,公司董事会审 议通过议案,同意全资子公司大兴安岭北极蓝食品有限公司对外出售土地、厂房等资产。本次拟出售 的资产账面原值合计5500.96万元。 8月18日晚间,沪深两市多家上市公司发布公告,以下是第一财经对一些重要公告的汇总,供投资者 参考。 【品大事】 中国重工:上交所受理公司股票主动终止上市申请 中国重工公告称,公司已于2025年8月14日向上海证券交易所提交股票主动终止上市的申请,并于8 月18日收到上交所出具的《关于受理中国船舶重工股份有限公司股票主动终止上市申请的通知》。 根据通知,上交所决定受理公司股票主动终止上市的申请。公司将在上交所批准后刊登相关终止上市 公告。 两连板申联生物:艾滋病单克隆抗体等创新药管线由联营公司独立运营 申联生物发布异动公告,公司目前的主营业务是兽用生物制品,艾滋病单克隆抗体等创新药管线由联 营公司扬州世之源生物科技有限责任公司独立运营,相关业务具有研发周期长,投入大,研发风险高 的特点。 两连板影石创新:全景无人机产品目前并未产生实 ...
20CM两连板申联生物:艾滋病单克隆抗体等创新药管线由联营公司独立运营
Mei Ri Jing Ji Xin Wen· 2025-08-18 09:05
Group 1 - The core business of the company is veterinary biological products, while the innovative drug pipeline, including AIDS monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [2] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [2]
生物股份:子公司获得兽用生物制品临床试验批件
news flash· 2025-07-25 08:29
Core Viewpoint - The company has received clinical trial approval for its mRNA vaccine targeting feline infectious peritonitis, marking a significant milestone in the development of veterinary nucleic acid vaccines [1] Group 1 - The company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has obtained the clinical trial approval from the Ministry of Agriculture and Rural Affairs for the feline infectious peritonitis mRNA vaccine [1] - This mRNA vaccine is categorized as a novel innovative vaccine, indicating advancements in vaccine technology [1] - The company is the first in the country to receive clinical approval for a veterinary nucleic acid vaccine targeting feline infectious peritonitis, establishing a foundation for future development in this area [1]
瑞普生物:获得兽用生物制品临床试验批件
news flash· 2025-07-25 07:45
Core Viewpoint - The announcement indicates that the company has received clinical trial approval for its mRNA vaccine targeting porcine epidemic diarrhea virus, marking a significant milestone in the veterinary vaccine sector in China [1] Group 1 - The company has obtained the clinical trial approval for the porcine epidemic diarrhea virus mRNA vaccine (RPS1903) from the Ministry of Agriculture and Rural Affairs [1] - This approval represents the first clinical trial permit for an mRNA vaccine for economic animals in China [1] - The achievement highlights the company's established mRNA vaccine research and development platform for veterinary use, which is expected to broaden its product line and development potential [1] Group 2 - The approval is anticipated to enhance the company's visibility and influence within the industry [1]
金宇生物技术股份有限公司股票交易异常波动公告
Shang Hai Zheng Quan Bao· 2025-07-17 19:19
Core Viewpoint - The stock of Jinyu Biotechnology Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 15 to July 17, 2025, triggering the abnormal fluctuation standards set by the Shanghai Stock Exchange [2][3]. Group 1: Stock Trading Abnormalities - The stock price of Jinyu Biotechnology rose significantly, with a cumulative increase of over 20% during the specified trading days [2][3]. - The company confirmed that its production and operational conditions remain normal, with no significant changes in the external business environment [4]. Group 2: Financial Performance - The company anticipates a net profit attributable to shareholders of between 57 million to 70 million yuan for the first half of 2025, representing a decrease of 52.92 million to 65.92 million yuan compared to the same period last year, which is a year-on-year decline of 43.05% to 53.63% [4]. - The expected net profit after deducting non-recurring gains and losses is projected to be between 30 million to 44 million yuan, reflecting a decrease of 63.86 million to 77.86 million yuan year-on-year, a decline of 59.21% to 72.19% [4]. Group 3: Major Events and Developments - The company’s wholly-owned subsidiary, Jinyu Baoling, received a clinical trial approval for an African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs [5][12]. - The vaccine development has involved a cumulative investment of approximately 64 million yuan [13]. Group 4: Shareholder and Management Actions - The company’s major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., confirmed that there are no undisclosed significant matters related to the company, including major asset restructuring or significant transactions [5][8]. - There were no stock trading activities by the company’s directors, senior management, or major shareholders during the period of abnormal stock price fluctuations [8].
生物股份:获得兽用生物制品临床试验批件
news flash· 2025-07-17 08:37
Core Viewpoint - The company has received clinical trial approval for its African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs, marking a significant step in its vaccine development efforts [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has been granted the clinical trial approval (Approval No: 2025058) for the African swine fever vaccine [1] - The vaccine is specifically designed to prevent African swine fever virus infections, indicating a targeted approach to addressing this critical issue in the livestock industry [1] - The company has invested approximately 64 million yuan in research and development for this vaccine in collaboration with research institutions since 2023 [1] Group 2: Clinical Trial Process - The clinical trials will be conducted at Jinyu Baoling, and the vaccine must complete these trials and undergo registration application before it can be marketed and sold [1] - Approval from regulatory bodies is required after the completion of clinical trials, highlighting the importance of compliance in the pharmaceutical development process [1]
资本腾挪后业绩倍增 海利生物遭问询
Zhong Guo Jing Ying Bao· 2025-07-04 19:51
Core Insights - The company, Haili Biological (603718.SH), reported a significant net profit increase of 172.28% in 2024, with non-recurring gains accounting for 93.82% of net profit, despite a revenue decline in Q1 2025 [2][5][8] - Haili Biological has transitioned from animal health products to human health products, leading to a substantial restructuring of its business model [2][9] Financial Performance - In 2024, Haili Biological's net profit reached approximately 1.71 billion yuan, with a notable increase attributed to asset disposals and acquisitions [4][5] - The company achieved an investment return exceeding 1 billion yuan from the sale of a 30% stake in WuXi Vaccines, which had previously generated low returns [5][6] - The sale of Yangling Jinhai at a nominal price of 1 yuan was a strategic move to eliminate ongoing losses, with the company recovering all debts owed by Yangling Jinhai [6][8] Asset Management - Haili Biological completed the acquisition of a 55% stake in Shaanxi Ruisheng Biotechnology, which is focused on oral tissue repair and regeneration materials, resulting in a goodwill of approximately 782 million yuan [9][10] - The company has prioritized finding quality projects in the oral and IVD sectors following the restructuring, although it acknowledges the challenges in identifying such opportunities [3][9] Market Dynamics - The oral vaccine market, particularly for foot-and-mouth disease, is facing increased competition and declining profitability, prompting Haili Biological to divest from Yangling Jinhai [7][8] - The revenue from Ruisheng Biotechnology in 2024 was approximately 265 million yuan, slightly below expectations, but the net profit exceeded targets [11]
天康制药拟北交所IPO,去年董事长、董秘、财务负责人均更换
Sou Hu Cai Jing· 2025-06-07 02:19
Core Viewpoint - TianKang Pharmaceutical Co., Ltd. has completed its IPO counseling work with CITIC Securities, indicating a move towards public listing despite recent declines in revenue and profit [1][2]. Financial Performance - In 2024, TianKang Pharmaceutical reported a revenue of 1.052 billion yuan, a decrease of 0.29% year-on-year, and a net profit attributable to shareholders of 153 million yuan, down 8.44% [1]. - For the first quarter of 2025, the company generated a revenue of 220 million yuan, a decline of 28.32% compared to 307 million yuan in the same period of 2024, with a net profit of approximately 33.33 million yuan, down 52.16% from 69.66 million yuan [3]. Shareholding Structure - The two largest shareholders of TianKang Pharmaceutical are TianKang Biological Co., Ltd. holding 58.94% and Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. holding 10% [3]. - Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd. holds 22.92% of TianKang Biological Co., Ltd., making it the controlling shareholder [3]. Management Changes - In 2024, several key management changes occurred: Chairman Yang Yan and Supervisor Zhao Qin resigned due to retirement age, while Pan Yiping was reassigned due to internal adjustments [4][5]. - Zhang Jie was appointed as the new Chairman, and other new appointments included Hao Yiding as Secretary of the Board and Kong Chuxin as Supervisor and Chairman of the Supervisory Board [5][6].